Ausgabe 2/2008
Inhalt (11 Artikel)
Atypical cytostatic mechanism of N-1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis
Fran Supek, Marijeta Kralj, Marko Marjanović, Lidija Šuman, Tomislav Šmuc, Irena Krizmanić, Biserka Žinić
NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2
Miguel Muñoz, Marisa Rosso, Francisco J Aguilar, Miguel A González-Moles, Maximino Redondo, Francisco Esteban
Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat
Qi-Biao Su, Fan He, Xue-Ding Wang, Su Guan, Zhi-Yong Xie, Lai-You Wang, Yu-Jing Lu, Lian-Quan Gu, Zhi-Shu Huang, Xiao Chen, Min Huang, Shu-Feng Zhou
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Markus Jensen, Andreas Engert, Florian Weissinger, Wolfgang Knauf, Eva Kimby, Christopher Poynton, Ira Anton Oliff, Mathias J. Rummel, Anders Österborg
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium
Thomas E. Hutson, Svetislava Vukelja, Daniel Atienza, Sanjay Awasthi, Robert Delaune, Margaret Deutsch, Philip Y. Dien, Thomas F. Gregory, Michael J. Kolodziej, Joseph J. Muscato, Robert N. Raju, Robert L. Ruxer Jr, Stephanie Mull, Des Ilegbodu, Karen Hood, Steven Nicol, William Berry
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
Patricia M. LoRusso, Shirish M. Gadgeel, Antoinette Wozniak, Alan J. Barge, Helen K. Jones, Zachary S. DelProposto, Pamela A. DeLuca, Jeffrey L. Evelhoch, Scott A. Boerner, Catherine Wheeler
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
Brigette Ma, Boon Cher Goh, Eng Huat Tan, Kwok Chi Lam, Ross Soo, Swan Swan Leong, Ling Zhi Wang, Frankie Mo, Anthony T. C. Chan, Benny Zee, Tony Mok
The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas
Paolo Andrea Zucali, Alexia Bertuzzi, Hector Jose Soto Parra, Elisabetta Campagnoli, Vittorio Quagliuolo, Armando Santoro
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
Athanassios Argiris, Sanjiv S. Agarwala, Michalis V. Karamouzis, Lynn A. Burmeister, Sally E. Carty
Topical henna for capecitabine induced hand–foot syndrome
Idris Yucel, Gonullu Guzin
A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)
J. J. Knox, X. E. Chen, R. Feld, M. Nematollahi, R. Cheiken, G. Pond, J. A. Zwiebel, S. Gill, M. Moore